Mechanisms of Drug Resistance 2

• 1781 · PDF 改善胰腺癌对氯沙坦的反应：机制洞见及对个体化治疗的意义 Improving response of pancreatic cancer to losartan: Mechanistic insights and implications for personalized therapy Heena Kumra, Ryo Morisue, Benjamin E. Wolf, Vasiliki Salameti, Sonu Subudhi, Nilesh P. Talele, Eric F. Zaniewski, Robert Morris, Tsion H. Tale, Karim El-Marouk, Cora Schueller, Mariagiovanna Barresi, Jennifer Schulz, Halil I. Corbali, Rieke Schleinhege, Peigen Huang, Pascal Bernatchez, Wilhelm Haas, Yves Boucher, Dai Fukumura, Rakesh K. Jain
• 1782 · PDF 外显子组规模的CRISPR筛选揭示高危神经母细胞瘤中细胞状态维持的主控因子 Exome-scale CRISPR screening reveals master controllers of cell state maintenance in high-risk neuroblastoma Grace McKay-Corkum, Stephanie Nance, Noha AM Shendy, Shilpa Narina, Shondra Miller, Alex Carisey, Qiqi Jin, Jiyang Yu, Adam D. Durbin
• 1783 · PDF ELF3驱动的表观遗传重编程在SERD耐药的ER+乳腺癌中造成ERK通路依赖性 ELF3-driven epigenetic reprogramming creates ERK pathway dependency in SERD-resistant ER+ breast cancer Na Zhang, Myles A. Brown, Rongbin Zheng, Kaifu Chen
• 1784 · PDF (Z)-endoxifen在ESR1突变型和内分泌耐药乳腺癌中的机制表征 Mechanistic characterization of (Z)-endoxifen in ESR1-mutant and endocrine-resistant breast cancer Sandra Suarez Hammer, Alina Ustiugova, Anastasia Shneyderman, Alexander Veviorskiy, Khadija M. Alawi, Mikhail Korzinkin, Lucia Beaulieu, Hayley Erickson, Scott M. Blackburn, H. Lawrence Remmel, Steven Quay
• 1785 · PDF 肝细胞癌中YBX1依赖性耐药机制的若干方面 Aspects of the YBX1-dependent mechanism of drug resistance in hepatocellular carcinoma Yamile Abuchard Anaya, Ana Ayala Pazzi, Veerababu Nagati, Kaylee Renteria, Denise Soto, Manish Tripathi
• 1786 · PDF FGFR-JAK信号的汇聚重编程管腔身份并驱动HR⁺乳腺癌的内分泌治疗耐药 Convergent FGFR-JAK signaling reprograms luminal identity and drives endocrine resistance in HR⁺ breast cancer Yucheng Zeng, Ruixin Liu, Xiaoyan Qiang, Jean Fan, Caixia Sun, Hanlin Zeng, Peng Peng
• 1787 · PDF 抑制MAOA可抑制细胞内分泌型雄激素生物合成并增强去势抵抗性前列腺癌的阿比特龙治疗 Inhibition of MAOA suppresses intracrine androgen biosynthesis and enhances abiraterone treatment in castration-resistant prostate cancer Kaisheng Yuan, Hongling Li, Wen Guan, Jing Wei, Boyang Wu
• 1788 · PDF 半胱氨酸积累作为硼替佐米耐药的驱动因素 Cysteine accumulation as a driver of resistance to bortezomib Jennifer A. Brain, Sarah M. Chang, Maximilian Kobiesa, Leah G. Rector, Kelli J. Che, Zhaoqi Li, Sky H. Kim, Matthew G. Vander Heiden, Lucas B. Sullivan
• 1789 · PDF 利用SMART-Seq® mRNA Long Read（v1和v2）试剂盒进行RNA异构体发现与定量 RNA isoform discovery and quantification with SMART-Seq® mRNA Long Read (v1 and v2) kits Jackson Peterson, Yue Yun, Lisa Welter, Kazuo Tori, Alan Du, Yana Ryan, Ning Ma, Rachana Kumar, Shiyi Yin, Mike Covington, Shuwen Chen, Elena Shagisultanova, Mohammad Fallahi, Bryan Bell, Andrew Farmer
• 1791 · PDF 靶向琥珀酸脱氢酶损害ER+乳腺癌细胞的增殖 Targeting succinate dehydrogenase impairs the proliferation of ER+ breast cancer cells Anil Kumar Yadav, Lu Jin, Robert Clarke
• 1792 1792 全面鉴定参与多发性骨髓瘤细胞中一种新型cereblon调节剂耐药机制的因素 Comprehensive identification of factors involved in the resistance mechanism of a novel cereblon modulator in multiple myeloma cells Sho Osawa, Tomofumi Yamamoto, Rina Tamaru, Natsumi Seki, Maiko Matsushita
• 1793 · PDF RAC2作为三阴性乳腺癌药物耐药的介导因子 RAC2 as a mediator of drug resistance in triple-negative breast cancer Antonisha R. McIntosh, Ngoc Voung, Destiny Ball, Perrin Black, Alayjha Edwards, Qingguo Wang, Amos M. Sakwe
• 1794 · PDF m⁶A介导的内分泌治疗耐药乳腺癌激酶重编程的调控 m 6 A-mediated control of kinase reprogramming in endocrine therapy-resistant breast cancer Attila Szenasi, Enakshi Sivasudhan, Santiago Haase, Austin Whitman, Kate D. Meyer, Philip M. Spanheimer
• 1795 · PDF ESR1突变与midasin在内分泌耐药中的协同作用及双靶向治疗潜力 Cooperative role of ESR1 mutations and midasin in endocrine resistance and the therapeutic potential of dual targeting Mounika Pamukuntla, Bipika Banjara, Manasa Kotina, Afia Ohemeng, Alicia Hudson, Michael Davidson, Jillian L. Pope, Selina F. Darling-Reed, Elizabeth Henderson, Simak Ali, Syreeta Tilghman
• 1796 · PDF 谱系特异性生存型与增殖型enzalutamide耐药状态作为前列腺癌差异的潜在驱动因素 Lineage-specific survival vs proliferative enzalutamide resistance states as potential drivers of prostate cancer disparities Richard Van, Mira V. Han, Desh P. Sharma, Ajay Singh, Ranjana Mitra
• 1798 · PDF 烟酰胺磷酸核糖转移酶（NAMPT）抑制剂耐药的横纹肌肉瘤（RMS）模型表现出代谢和基因组特征的改变 Nicotinamide phosphoribosyltransferase (NAMPT) inhibitor-resistant rhabdomyosarcoma (RMS) models exhibit alterations in metabolic and genomic profiles Ariana Elizabeth Nelson, Abantika Chakraborty, David Bell, Victor J. Collins, Ali Mokhtar Mahmoud, Ying Wu, SOPHIA VARRIANO, Arnulfo Mendoza, Sameer Issaq, Parthav Jailwala, Jack F. Shern, Ernesto Suárez, Joseph Ivanic, Christine M. Heske
• 1799 · PDF 铁转运蛋白介导卵巢癌中的bevacizumab耐药和铁死亡逃逸 Ferroportin mediates bevacizumab resistance and ferroptosis evasion in ovarian cancer Zonghao Tang, Amir A. Jazaeri, Weiche Wu, Mark Kim, Shannon N. Westin, Timothy A. Yap, Sanghoon Lee, Anil K. Sood
• 1800 · PDF 线粒体功能障碍诱导R-spondin融合结直肠癌中的天冬酰胺酶耐药 Mitochondrial dysfunction induces asparaginase resistance in R-spondin fusion colorectal cancer Su Hyun Lee, Yun-Cheol Chae, Alejandro Gutierrez
• 1801 · PDF 幽门螺杆菌感染诱导WEE1促进胃腺癌的耐药 H. pylori infection induces WEE1 to promote drug resistance in gastric adenocarcinoma Md Obaidul Islam, Krishnapriya Thangaretnam, Jialun Lyu, Zhenzhen Zhang, Heng Lu, Dunfa Peng, Nadeem Sidiq Bhat, Mohammed Soutto, Wael El Rifai, Zheng Chen
• 1802 · PDF 成纤维细胞驱动的ER+乳腺癌tamoxifen耐药：实验验证与高通量共培养筛选试验的开发 Fibroblast-driven tamoxifen resistance in ER+ breast cancer: Experimental validation and development of a high-throughput co-culture screening assay Elisabet Rodríguez-Tomàs, Francesco Massai, Arne Östman
• 1803 · PDF 动态拷贝数变化和染色体外DNA的从头生成调控治疗耐药 Dynamic copy number changes and de novo generation of extrachromosomal DNA modulate therapy resistance Tim Vorberg, Manuel Reitberger, Bernardo Rodriguez Martin, Maja Starostecka, Dominique Schulz, Arlou K. Angeles, Kate I. Glennon, Tasneem Cheytan, Roberto Würth, Vera Thiel, Paul Schwerd-Kleine, Verena Thewes, Laura Michel, Ewgenija Gutjahr, Simon J. Ogrodnik, Heike Conrad, Steffi O. Mehlhorn, Vanessa Vogel, Corinna Klein, Albrecht Stenzinger, Peter Lichter, Andreas Schneeweiss, Martin Granzow, Marc Zapatka, Anna Jauch, Holger Sültmann, Jan Korbel, Andreas Trumpp, Martin R. Sprick
• 1804 · PDF Midasin抑制破坏sumoylation轴，通过改变转录网络损害乳腺球体稳定性 Midasin inhibition disrupts the sumoylation axis to impair mammosphere stability through alteration of transcriptional network Bipika Banjara, Mounika Pamukuntla, Manasa Kotina, Afia Ohemeng, Alicia Hudson, A. Michael Davidson, Jillian L. Pope, Selina F. Darling-Reed, Syreeta Tilghman
• 1805 · PDF PASK（Per-Arnt-Sim激酶）抑制剂在可变葡萄糖条件下对三阴性乳腺癌疗效的血统依赖性差异 Ancestry-dependent differences of PASK (Per-Arnt-Sim Kinase) inhibitor efficacy in triple-negative breast cancer under variable glucose conditions Ayomide Olayiwola, Sree Aramgam, K. Sean Kimbro
• 1806 · PDF 手术刀下的WRN：HCT116和RKO中解旋酶结构域热点及剪接位点敲入 WRN under the scalpel: Helicase-domain hotspot & splice-site knock-ins in HCT116 and RKO Yue Huang, Xiaomeng Gou, Jinying Ning, Feng Hao
• 1807 · PDF RLIP耗竭抑制卵巢癌生长和转移 RLIP depletion suppresses ovarian cancer growth and metastasis Sharad S. Singhal, Madhu Krishna, Prakash Kulkarni, David Horne, Ravi Salgia
• 1808 1808 METTL7A和METTL7B赋予对口服巯基类组蛋白脱乙酰酶抑制剂ST7612AA1的耐药性 METTL7A and METTL7B confer resistance to the oral thiol-based histone deacetylase inhibitor ST7612AA1 Omotola D. Gbadegesin, Robert W. Robey, Michael M. Gottesman
• 5291 · PDF TKI耐药RCC中EZH2-AR非经典轴的激活：lenvatinib与cabozantinib的差异性效应 EZH2-AR non-canonical axis activation in TKI-resistant RCC: Differential effects of lenvatinib and cabozantinib Christian Migliarese, Abbas Jawadwala, Sabrina A. Orsi, Stephanie Metcalf, Saranya Rajendran, Peter C. Hollenhorst, Roberto Pili

在会议检索中浏览本分会场